Our group previously developed a highly potent STAT3 PROTAC degrader with excellent tumor inhibitory effects in leukemia and lymphoma cell lines, supporting the notion that PROTAC degraders have the potential to be developed for clinical use67. This evidence concerns the gene STAT3 and lymphoma.